India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Ongoing trials of the next generation of weight loss drugs are revealing something unexpected: Some patients are losing too ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...

The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Eli Lilly ...

Lilly plans to build four new pharmaceutical plants in the US, creating 13,000 jobs and bringing its recent domestic ...

Supplies of high-demand obesity treatments are improving, but that doesn’t mean it’s easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key ...

Eli Lilly and Company, Hims & Hers Health, UnitedHealth Group, Walmart, Tempus AI, Johnson & Johnson, and Merck & Co., Inc. are the seven Medical stocks to watch today, according to MarketBeat’s stock ...